Terumo Introduces AZUR Vascular Plug, PG Pro Embolization System

Terumo Medical Corporation (TMC) has introduced its AZUR Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo’s robust embolization portfolio is indicated for use to reduce or block the rate of blood flow in arteries of the peripheral vasculature.
 
“The AZUR Vascular Plug represents a balance of properties—stability, accuracy, and reliable occlusion. This technology has unique advantages that truly make it a market first in embolotherapy, in line with Terumo’s ongoing efforts to deliver improved clinical outcomes and economic benefits,” said Chris Pearson, executive vice president, Commercial Operations, Terumo Interventional Systems.
 
The AZUR Vascular Plug comes in sizes to treat arterial anatomy ranging from 2.5mm to 8mm, with a short deployment length for increased precision. Features include a conformable nitinol braid that stays in place, even in tortuous anatomy. It also comes with a polytetrafluoroethylene (ePTFE) and polyethylene terephthalate (PET) inner composite membrane to facilitate mechanical occlusion. Another key element in the Plug’s design is its advanced, predictable detachment mechanism that allows for immediate and reliable deployment with the push of a button. Consistent with Terumo’s existing Azur coil portfolio, this state-of-the-art detachment mechanism can allow for a full ability to reposition, while making the process much smoother than traditional twist-off detachment mechanisms. 
 
The launch of AZUR Vascular Plug is complemented by the introduction of the PG Pro Peripheral Microcatheter, which is indicated for the peripheral vasculature for the infusion of diagnostic and therapeutic agents. The PG Pro Microcatheter is designed specifically to deliver all three sizes of the Azur Vascular Plug. It comes in radial lengths up to 165 centimeters and a 1200 PSI rating for clearer fluoroscopic imaging. Both are currently only available in the United States.
 
“Together, these next generation technologies allow physicians to treat larger, more difficult vessels through smaller delivery options. It is yet another way Terumo is providing the opportunity for operators to take advantage of the benefits of radial access for increasingly complex procedures, while enhancing therapeutic options in the peripheral vasculature with a microvascular plug. It is a welcome addition to our innovative, best-in-class portfolio,” added Michael Martinelli, M.D., chief medical officer, Terumo Medical Corporation. 
 
Terumo Medical Corporation (TMC) is a subsidiary of Terumo Corporation, founded in 1972 as the United States expansion of its larger Tokyo-based parent. For nearly 50 years, TMC has continued the Terumo mission of offering the best possible solutions to healthcare providers and the people it serves. TMC provides products and services across four divisions: Terumo Business Edge, which provides healthcare systems with solutions designed to reduce care variation, improve quality metrics, minimize cost and maximize revenue; Terumo Interventional Systems (TIS), which offers solutions for entry site management, embolization and lesion access; Terumo Medical Products (TMP), which provides devices for injection and infusion therapy; and Terumo Pharmaceutical Solutions (TPS), which develops drug delivery devices.
 
Terumo is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.